Metraipolis › archive › dc_528273f0bb67

The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies — Europe PMC PMID:41429239

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41429239
DOI
10.1016/j.bbcan.2025.189519
License (as archived)
solo-consultazione
Archived
2026-11-07T12:12:26.701Z
SHA-256 of the archived text
88cfca40e415281a51782d3f8b60dbe411143575ec78e93e283aa4b3b08c6879
Stable URL of this page
https://metraipolis.com/documento/dc_528273f0bb67

How to cite

The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies — Europe PMC PMID:41429239 — Europe PMC (en), https://europepmc.org/article/MED/41429239 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_528273f0bb67 (Metraipolis archive dc_528273f0bb67, sha256 88cfca40e415281a51782d3f8b60dbe411143575ec78e93e283aa4b3b08c6879)
BibTeX
@misc{dc528273f0bb67,
  title = {The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies — Europe PMC PMID:41429239},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41429239},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_528273f0bb67; sha256 88cfca40e415281a51782d3f8b60dbe411143575ec78e93e283aa4b3b08c6879},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41429239. Agents can read the archived copy with the MCP tool read_document.